The National Cancer Institute (NCI) invites applications for Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) to join its PDXNet program. This grant supports the collaborative development and preclinical testing of targeted therapeutic agents in patient-derived models, advancing cancer precision medicine. PDTCs will conduct mechanism-based preclinical trials of drug combinations in PDXs, focusing on NCI-IND agents, to recommend candidates for early-phase clinical trials. Key objectives include developing new PDX models to fill resource gaps, particularly from diverse populations and rare cancers, and sharing these with the NCI Patient Derived Models Repository. Furthermore, the initiative seeks to enhance metrics for predicting clinical outcomes, address therapeutic outcome disparities, and facilitate broad data sharing across the cancer research community.
Opportunity ID: 338953
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-22-012 |
| Funding Opportunity Title: | Patient Derived Xenograft (PDX) Development and Trial Centers (PDTCs) Network (U54 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.394 — Cancer Detection and Diagnosis Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 25, 2022 |
| Last Updated Date: | Mar 25, 2022 |
| Original Closing Date for Applications: | Nov 01, 2022 |
| Current Closing Date for Applications: | Nov 01, 2022 |
| Archive Date: | Dec 07, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments County governments Small businesses For profit organizations other than small businesses Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity announcement (FOA) requests applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models (PDMs) to advance the vision of cancer precision medicine. The main goals for PDTCs include: develop and implement mechanism-based preclinical trials of drug combinations in large sets of molecularly characterized PDXs to advance cancer precision medicine through the therapeutic development of these agents, with a focus on NCI-IND agents; provide evidence-based recommendations for early phase clinical trials to be conducted in NCI clinical trial networks by identifying agent combinations that produce in vivo evidence of deep and durable responses of PDX models to the therapeutic intervention; develop and characterize new PDX models to share with the NCI Patient Derived Models Repository (PDMR) that fill identified resource gaps in the PDMR collection. This includes PDX models from patients with clinical drug resistance, models obtained from racial/ethnic minority populations, and models of rare cancers; engage collaboratively as a network to develop and apply metrics for preclinical in vivo drug response that improves the value of PDX drug response data in predicting clinical outcomes; advance the understanding of therapeutic outcome disparities by race/ethnicity to ensure that early phase clinical trials are well equipped to support diverse and equitable recruitment; and devise procedures and platforms to make preclinical PDX data broadly available to researchers across the cancer community, using PDTCs and NCI mutually agreed upon standards. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-012.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00272793 | Oct 01, 2022 | Nov 01, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277509 | Oct 27, 2022 | Nov 01, 2022 | View |
Package 1
Mandatory forms
338953 RR_SF424_5_0-5.0.pdf
338953 PHS398_CoverPageSupplement_5_0-5.0.pdf
338953 RR_OtherProjectInfo_1_4-1.4.pdf
338953 PerformanceSite_4_0-4.0.pdf
338953 RR_KeyPersonExpanded_4_0-4.0.pdf
338953 PHS398_ResearchPlan_4_0-4.0.pdf
338953 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
338953 PHS_Additional_IndirectCosts_2_0-2.0.pdf
338953 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
338953 RR_SF424_5_0-5.0.pdf
338953 PHS398_CoverPageSupplement_5_0-5.0.pdf
338953 RR_OtherProjectInfo_1_4-1.4.pdf
338953 PerformanceSite_4_0-4.0.pdf
338953 RR_KeyPersonExpanded_4_0-4.0.pdf
338953 PHS398_ResearchPlan_5_0-5.0.pdf
338953 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
338953 PHS_Additional_IndirectCosts_2_0-2.0.pdf
338953 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
